



Supplementary material

Supplementary Figure 1: The FluidCrystal® drug delivery system¹⁻⁵



In ACROINNOVA 1, CAM2029 was administered via pre-filled syringes.⁵ Only the pre-filled autoinjector is available following marketing authorization.⁶

Supplementary Figure 2: Overview of the Acromegaly Index of Severity



ACROINNOVA 1 and 2 were not powered to assess changes in acromegaly symptom severity using the AIS. *In ACROINNOVA 1 and 2, paresthesia was included in addition to the five symptoms assessed with the AIS in Fleseriu *et al* 2020.^{5,7}

Supplementary Table 1: Patient demographics and medical history

	All assessments N=122	On-time assessment (≤28 days) N=86	Later assessment (>28 days) N=36
Mean age, years (SD)	53 (11.7)	52 (11.4)	55 (12.2)
Sex, n (%)			
Female	70 (57.4)	51 (59.3)	19 (52.8)
Male	52 (42.6)	35 (40.7)	17 (47.2)
Mean time since diagnosis, years (SD)	11 (7.8)	10 (7.6)	12 (8.1)
Prior pituitary surgery history, n (%)	108 (88.5)	79 (91.9)	29 (80.6)
Baseline treatment, n (%)			
Octreotide LAR	79 (64.8)	55 (64.0)	24 (66.7)
Lanreotide ATG	43 (35.2)	31 (36.0)	12 (33.3)

ATG, Autogel; LAR, long-acting repeatable; SD, standard deviation.

References

1. Tiberg F *et al.* *Chem Lett* 2012;41:1090–2.
2. Tiberg F, Johnsson M. *J Drug Deliv Sci Technol* 2011;21:101–9.
3. Engstedt J *et al.* *Colloids Surf B Biointerfaces* 2024;239:113955.
4. Tiberg F *et al.* *Br J Clin Pharmacol* 2015;80:460–72.
5. Ferone D *et al.* *J Clin Endocrinol Metab* 2025;110:1729–39.
6. Camurus AB. Ocyyesa® (octreotide). EU summary of Product Characteristics, 2025.
7. Fleseriu M *et al.* *Pituitary* 2020;23:347–58.
8. Fleseriu M *et al.* *Front Endocrinol* 2021;12:627711.